Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline?
Mismanagement of bacterial infection therapies has undermined the reliability and efficacy of antibiotic treatments, producing a profound crisis of the antibiotic drug market. It is by now clear that tackling deadly infections demands novel strategies not only based on the mere toxicity of anti-infe...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/12/7/624 |
| _version_ | 1797563317175189504 |
|---|---|
| author | Matteo Puccetti Styliani Xiroudaki Maurizio Ricci Stefano Giovagnoli |
| author_facet | Matteo Puccetti Styliani Xiroudaki Maurizio Ricci Stefano Giovagnoli |
| author_sort | Matteo Puccetti |
| collection | DOAJ |
| description | Mismanagement of bacterial infection therapies has undermined the reliability and efficacy of antibiotic treatments, producing a profound crisis of the antibiotic drug market. It is by now clear that tackling deadly infections demands novel strategies not only based on the mere toxicity of anti-infective compounds. Host-directed therapies have been the first example as novel treatments with alternate success. Nevertheless, recent advances in the human microbiome research have provided evidence that compounds produced by the microbial metabolism, namely postbiotics, can have significant impact on human health. Such compounds target the host-microbe-pathogen interface rescuing biotic and immune unbalances as well as inflammation, thus providing novel therapeutic opportunities. This work discusses critically, through literature review and personal contributions, these novel nonantibiotic treatment strategies for infectious disease management and resistance prevention, which could represent a paradigm change rocking the foundation of current antibiotic therapy tenets. |
| first_indexed | 2024-03-10T18:41:55Z |
| format | Article |
| id | doaj.art-cde6b9a0e6bd426fa73010f4f7acaf04 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T18:41:55Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-cde6b9a0e6bd426fa73010f4f7acaf042023-11-20T05:50:15ZengMDPI AGPharmaceutics1999-49232020-07-0112762410.3390/pharmaceutics12070624Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline?Matteo Puccetti0Styliani Xiroudaki1Maurizio Ricci2Stefano Giovagnoli3Department of Pharmaceutical Sciences, via del Liceo 1, University of Perugia, 06123 Perugia, ItalyDepartment of Pharmaceutical Sciences, via del Liceo 1, University of Perugia, 06123 Perugia, ItalyDepartment of Pharmaceutical Sciences, via del Liceo 1, University of Perugia, 06123 Perugia, ItalyDepartment of Pharmaceutical Sciences, via del Liceo 1, University of Perugia, 06123 Perugia, ItalyMismanagement of bacterial infection therapies has undermined the reliability and efficacy of antibiotic treatments, producing a profound crisis of the antibiotic drug market. It is by now clear that tackling deadly infections demands novel strategies not only based on the mere toxicity of anti-infective compounds. Host-directed therapies have been the first example as novel treatments with alternate success. Nevertheless, recent advances in the human microbiome research have provided evidence that compounds produced by the microbial metabolism, namely postbiotics, can have significant impact on human health. Such compounds target the host-microbe-pathogen interface rescuing biotic and immune unbalances as well as inflammation, thus providing novel therapeutic opportunities. This work discusses critically, through literature review and personal contributions, these novel nonantibiotic treatment strategies for infectious disease management and resistance prevention, which could represent a paradigm change rocking the foundation of current antibiotic therapy tenets.https://www.mdpi.com/1999-4923/12/7/624infectious diseases3-indole carboxaldehydemicrobiotahost-microbiota-pathogen interfaceantimicrobial resistancepostbiotics |
| spellingShingle | Matteo Puccetti Styliani Xiroudaki Maurizio Ricci Stefano Giovagnoli Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline? Pharmaceutics infectious diseases 3-indole carboxaldehyde microbiota host-microbiota-pathogen interface antimicrobial resistance postbiotics |
| title | Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline? |
| title_full | Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline? |
| title_fullStr | Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline? |
| title_full_unstemmed | Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline? |
| title_short | Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline? |
| title_sort | postbiotic enabled targeting of the host microbiota pathogen interface hints of antibiotic decline |
| topic | infectious diseases 3-indole carboxaldehyde microbiota host-microbiota-pathogen interface antimicrobial resistance postbiotics |
| url | https://www.mdpi.com/1999-4923/12/7/624 |
| work_keys_str_mv | AT matteopuccetti postbioticenabledtargetingofthehostmicrobiotapathogeninterfacehintsofantibioticdecline AT stylianixiroudaki postbioticenabledtargetingofthehostmicrobiotapathogeninterfacehintsofantibioticdecline AT maurizioricci postbioticenabledtargetingofthehostmicrobiotapathogeninterfacehintsofantibioticdecline AT stefanogiovagnoli postbioticenabledtargetingofthehostmicrobiotapathogeninterfacehintsofantibioticdecline |